Early breast cancer

The Lancet

Volumn 373, Issue 9673, 2009, Pages 1463-1479

  Benson, John R ^a   Jatoi, Ismail ^b   Keisch, Martin ^c   Esteva, Francisco J ^d   Makris, Andreas ^e   Jordan, V Craig ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c Aventura Hospital   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; PLACEBO; RALOXIFENE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; GENE EXPRESSION PROFILING; GENE MUTATION; HOT FLUSH; HUMAN; MAMMOGRAPHY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; TREATMENT RESPONSE;

EID: 64949128193     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60316-0     Document Type: Review

References (183)

1. Hortobagyi G.N., de la Garza Salazar J., Pritchard K., et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6 (2005) 391-401
2. Porter P. "Westernizing" women's risks? Breast cancer in lower-income countries. N Engl J Med 358 (2008) 213-216
3. Hankinson S.E., Colditz G.A., and Willett W.C. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res Treat 6 (2004) 213-218
4. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
5. Beral V., Hermon C., Reeves G., and Peto R. Sudden fall in breast cancer death rates in England and Wales. Lancet 345 (1995) 1642-1643
6. Peto R., Boreham J., Clarke M., Davies C., and Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355 (2000) 1822
7. Jatoi I., and Miller A.B. Why is breast-cancer mortality declining?. Lancet Oncol 4 (2003) 251-254
8. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784-1792
9. Jatoi I., Chen B.E., Anderson W.F., and Rosenberg P.S. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25 (2007) 1683-1690
10. Anderson W.F., Jatoi I., and Devesa S.S. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90 (2005) 127-137
11. Clemmesen J. Carcinoma of the breast; results from statistical research. Br J Rad 21 (1948) 583-590
12. Adami H.O., Hansen J., Jung B., and Rimsten A.J. Age at first birth, parity and risk of breast cancer in a Swedish population. Br J Cancer 42 (1980) 651-658
13. Cleary M.P., and Maihle N.J. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med (New York) 216 (1997) 28-43
14. Anderson W.F., Matsuno R.K., Sherman M.E., et al. Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. Cancer Causes Control 18 (2007) 439-447
15. Byrne C., Schairer C., Wolfe J., et al. Mammographic features and breast cancer risk: effects with time, age and menopausal status. J Natl Cancer Inst 87 (1995) 1622-1629
16. Jatoi I., Anderson W.F., Rao S.R., and Devesa S.S. Breast cancer trends among black and white women in the United States. J Clin Oncol 23 (2005) 7836-7841
17. Jatoi I., Becher H., and Leake C.R. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the US Department of Defense Healthcare system. Cancer 98 (2003) 894-899
18. Robson M., and Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357 (2007) 154-162
19. Ford D., and Easton D.F. The genetics of breast and ovarian cancer. Br J Cancer 72 (1995) 805-812
20. Merajver S.D., Pham T.M., Caduff R.F., et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9 (1995) 439-443
21. Baynes C., Healey C.S., Pooley K.A., et al. Common variants in the ATM, BRCA-1, BRCA-2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increased breast cancer risk. Breast Cancer Res Treat 9 (2007) R27
22. Ramazzini B. De Morbis Artificum. Editio Secunda. Ultrajecti: Apud Guilielmum van de Water Academiae Typographum (courtesy, The Bodleian Library, Oxford): 156.
23. Petrek J.A., Dukoff R., and Rogatko A. Prognosis of pregnancy-associated breast cancer. Cancer 67 (1991) 869-872
24. Colditz G.A. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 11 (2005) 909-917
25. Holmberg L., Iversen O.-E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (2008) 475-482
26. Monninkhof E.M., Elias S.G., Vlems F.A., et al. Physical activity and breast cancer: a systematic review. Epidemiology 18 (2007) 137-157
27. Zhang S.M., Lee I.M., Manson J.E., Cook N.R., Willett W.C., and Buring J.E. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol 165 (2007) 667-676
28. Santen R.J., Boyd N.F., Chlebowski R.T., et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 14 (2007) 169-187
29. Smith L.F. Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol 96 (2007) 451-452
30. Zonderland H.M., Coerkamp E.G., Hermans J., et al. Diagnosis of breast cancer: contributions of US as an adjunct to mammography. Radiology 213 (1999) 413-422
31. Britton P.D., and McCann J. Needle biopsy in the NHS Breast Screening Programme: how much and how accurate?. Breast 8 (1999) 5-11
32. Stanley M.W., Sidawy M.K., Sanchez M.A., Stahl R.E., and Goldfischer M. Current issues in breast cytopathology. Am J Clin Path 115 (2000) S49-S75
33. Helbich T.H., Matzek W., and Fuchsjager M.H. Stereotactic and ultrasound-guided breast biopsy. Eur Radiol 14 (2004) 383-393
34. Jackman R.J., Nowels K.W., Rodriguez-Soto J., et al. Sterotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long term follow up. Radiology 210 (1999) 799-805
35. DeMartini W., Lehman C., and Partridge S. Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol 15 (2008) 408-416
36. Mameri C.S., Kemp C., Goldman S.M., et al. Impact of breast MRI on surgical treatment, axillary approach, and systemic therapy for breast cancer. Breast J 14 (2008) 236-244
37. Morrow M., and Freedman G. A clinical oncology perspective on the use of breast MR. Magn Reson Imaging Clin N Am 14 (2006) 363-378
38. Solin L.J., Orel S.G., Hwang W.T., et al. Relationship of breast magnetic resonance imaging to outcome after breast conservation treatment with radiation for women with early stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26 (2008) 386-391
39. Morrow M. Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm. J Clin Oncol 26 (2008) 352-353
40. Gotzsche P.C., and Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 3 (2006) CD001877.
41. Moss S.M., Cuckle H., Evans A., Johns L., Waller M., and Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 (2006) 2053-2060
42. Barton M.B., Harris R., and Fletcher S.W. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?. JAMA 282 (1999) 1270-1280
43. Thomas D.B., Gao D.L., Ray R.M., et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (2002) 1445-1457
44. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 (2007) 75-89
45. della Rovere G.Q., and Benson J.R. Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis?. Lancet Oncol 3 (2002) 183-187
46. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
47. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure. The David A Karnofsky Memorial Lecture. Cancer Res 40 (1980) 3863-3874
48. Komoike Y., Akiyama F., Lino Y., et al. Ipsilateral breast tumour recurrence (IBTR) after breast conserving treatment for breast cancer. Cancer 106 (2005) 35-39
49. Early Breast Cancer Trialists Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
50. Huang E., Cheng S.H., Dressman H., et al. Gene expression predictors of breast cancer outcomes. Lancet 361 (2003) 1590-1596
51. Locker G., Sainsbury R., and Cuzick J. Breast surgery in the ATAC trial: women in the United States are more likely to have mastectomy. Breast Cancer Res Treat 76 (2002) S35
52. IBTR. Breast cancer model. http://www.nemc.org/ibtr (accessed Nov 17, 2008).
53. Taghian A., Mohiuddin M., Jagsi R., et al. Current perceptions regarding surgical margin status after breast conserving therapy: results of a survey. Ann Surg 241 (2005) 629-639
54. Singletary S.E. Surgical margins in patients with early stage breast cancer treated with breast conservation therapy. Am J Surg 184 (2002) 383-393
55. Morrow M., and Harris J.R. Practice guidelines for breast conserving therapy in the management of invasive breast cancer. J Am Coll Surg 205 (2007) 362-376
56. Cochrane R., Valasiadou P., Wilson A., et al. Cosmesis and satisfaction after breast conserving surgery correlates with percentage of breast volume excised. Br J Surg 90 (2003) 1505-1509
57. Taylor M.E., Perez C.A., Halverson K.J., et al. Factors influencing cosmetic results after conservation therapy for breast cancer. In J Rad Oncol Biol Phys 31 (1995) 753-764
58. McCulley S.J., and Macmillan R.D. Planning and use of therapeutic mammoplasty-Nottingham approach. Br J Plast Surg 58 (2005) 889-901
59. Asgeirsson K., McCulley S., Pinder S., and Macmillan R. Size of invasive breast cancer and risk of local recurrence after breast conservation therapy. Eur J Cancer 39 (2003) 2462-2469
60. Benson J.R., and Absar M.S. Volume replacement and displacement techniques in oncoplastic surgery. Advances in Breast Cancer 5 (2008) 1-7
61. Rivadeniera D.E., Simmons R.M., Fish S.K., et al. Skin-sparing mastectomy with immediate breast reconstruction: a critical analysis of local recurrence. Cancer J 6 (2000) 331-335
62. Overgaard M., Hansen P.S., Overgaard J., et al. Post-operative radiotherapy in high risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 337 (1997) 949-955
63. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node positive pre-menopausal women with breast cancer. N Engl J Med 337 (1997) 956-962
64. Behranwala K.A., Dua R.S., Ross G.M., et al. The influence of radiotherapy on capsule formation and aesthetic outcome after immediate breast reconstruction using biodimensional anatomical expander implants. J Plast Reconstr Aesthet Surg 59 (2006) 1043-1051
65. Lyman G.H., Guiliano A.E., Somerfield M.R., et al. The Americal Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early Stage Breast Cancer. J Clin Oncol 23 (2005) 7703-7720
66. Benson J.R., and della Rovere G.Q. Management of the axilla in women with breast cancer. Lancet Oncol 8 (2007) 331-348
67. Krag D.N., Anderson S.J., Julian T.B., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8 (2007) 881-888
68. Pal A., Provenzano E., Duffy S.W., et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95 (2008) 302-309
69. Park J., Fey J.V., Naik A.M., et al. A declining rate of completion axillary dissection in sentinel lymph node positive breast cancer patients is associated with the use of a multivariate nomogram. Breast Cancer Res Treat 100 (2005) S80 (abstract 2001).
70. Julian T.B., Blumencranz P., Deck K., et al. Novel intraoperative molecular test for sentinel lymph node metastasesin patients with early stage breast cancer. J Clin Oncol 26 (2008) 3338-3345
71. Naik A.M., Fey J., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg 240 (2004) 462-471
72. Kujit G.P., and Roumen R.M.H. Second thoughts on sentinel lymph node biopsy in node negative breast cancer. Br J Surg 95 (2008) 310-311
73. Veronesi U., Cascinelli N., Mariani L., et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347 (2002) 1227-1232
74. Smith I.E., and Ross G.M. Breast radiotherapy after lumpectomy-no longer always necessary. N Engl J Med 351 (2004) 1021-1023
75. Smith B.D., Gross C.P., Smith G.L., et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 98 (2006) 681-690
76. Clark R.M., McCulloch P.B., Levine M.N., et al. Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84 (1992) 683-689
77. Hughes K.S., Schnaper L.A., Berry D., et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351 (2004) 971-977
78. Fyles A.W., McCready D.R., Manchul L.A., et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351 (2004) 963-970
79. King T.A., Bolton J.S., Kuske R.R., et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is,1,2) breast cancer. Am J Surg 180 (2000) 299-304
80. Cuttino L.W., Arthur D.W., Todor D.A., et al. CT- guided multi-catheter insertion technique for partial breast brachytherapy (PBB): Reliable target coverage and dose homogeneity. Brachytherapy 2 (2003) 41-68
81. Vicini F.A., Kestin L., Chen P., et al. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 95 (2003) 1205-1210
82. Kuske R.R., Winter K., Arthur D.W., et al. Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: toxicity analysis of RTOG 95-17. Int J Radiat Oncol Biol Phys 65 (2006) 45-51
83. Vaidya J.S., Baum M., Tobias J.S., et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 12 (2001) 1075-1080
84. Veronesi U., Orrechia R., Luini A., et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 37 (2001) 2178-2183
85. Enderling H., Chaplain M.A., Anderson A.R., and Vaidya J.S. A mathematical model of breast cancer development, local treatment and recurrence. J Theor Biol 246 (2007) 245-259
86. Belletti B., Vaidya J.S., D'Andrea S., et al. Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wound healing. Clin Cancer Res 14 (2008) 1325-1332
87. Keisch M., Vicini F., Kuske R.R., et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 55 (2003) 289-293
88. Benitez P.R., Keisch M.E., Vicini F., et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 194 (2007) 456-462
89. Vicini F., Beitch P.D., Quiet C.A., et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (ABPI). Cancer 112 (2008) 758-766
90. Vicini F.A., Remouchamps V., Wallace M., et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 57 (2003) 1247-1253
91. Formenti S.C., Truong M.T., Goldberg J.D., et al. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 60 (2004) 493-504
92. Kestin L.L., Sharpe M.B., Frazier R.C., et al. Intensity modulation to improve dose uniformity with tangential breast radiotherapy: initial clinical experience. Int J Radiat Oncol Biol Phys 48 (2000) 1559-1568
93. Whelan T., MacKenzie R., Julian J., et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94 (2002) 1143-1150
94. The START trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trail A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9 (2008) 331-341
95. Kruegrer E.A., Fraass B.A., McShan D.L., et al. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1023-1037
96. MRC SUPREMO Trial. http://www.supremo-trial.com (accessed Nov 17, 2008).
97. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (1998) 930-942
98. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1461
99. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
100. Marchionni L., Wilson R.F., Wolff A.C., et al. Systematic review: gene expression profiling assays in early stage breast cancer. Ann Intern Med 148 (2008) 358-369
101. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
102. Scottish Cancer Trials Breast Group and IBU. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341 (1993) 1293-1298
103. Lyman G.H., Guiliano A.E., Somerfield M.R., et al. The American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early Stage Breast Cancer. J Clin Oncol 23 (2005) 7703-7720
104. ATAC Trialist's Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
105. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
106. Benson J.R. The use or aromatase inhibitors in post-menopausal women with hormone receptor positive breast cancer. J Clin Oncol 23 (2005) 6807-6809
107. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 year's tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
108. Jonat W., Gnant M., Boccado F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
109. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
110. Mouridsen H, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. 31st San Antonio Breast Cancer Symposium, Texas, USA; December, 2008.
111. Goss P.E., Ingle J.N., Martino S., et al. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
112. Clarke M., Coates A.S., Darby S.C., et al. Adjuvant chemotherapy in oestrogen receptor poor breast cancer: patient level meta-analysis of randomised trials. Lancet 371 (2008) 29-40
113. Carlson R.W., Brown E., Burstein H.J., et al. NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl Compr Cancer Netw 4 suppl (2006) S1-S26
114. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative, estrogen receptor positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
115. Roche H., Fumoleau P., Spielman M., et al. Sequential adjuvant epirubicin based and docetaxel chemotherapy for node positive breast cancer patients: The FNCLCC PACS001 trial. J Clin Oncol 24 (2006) 5664-5671
116. Albain K.S., Barlow W., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node positive, ER positive breast cancer. Breast Cancer Res Treat 96 (2007) 10A
117. Esteva F.J., Sahin A.A., Cristofanilli M., et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11 (2005) 3315-3319
118. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7 (2006) 347-350
119. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential Paclitaxel but not escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
120. Citron M.L., Berry D.A., Cirrincione C., et al. Randomised trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node positive primary breast cancer: first report of Intergroup Trial C. J Clin Oncol 21 (2003) 1431-1439
121. Martin M., Pienkowski T., Mackay J., et al. Adjuvant docetaxol for node positive breast cancer. N Engl J Med 352 (2005) 2302-2313
122. Sparano J.A., Wang M., Martino S., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358 (2008) 1663-1671
123. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with Paclitaxel and Fluorouracil, Doxorubicin and Cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
124. Ellis P.A., Barrett-Lee P.J., Bloomfield D., et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) trial. Breast Cancer Res Treat 106 (2007) S21 (abstract 78).
125. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node positive breast cancer. N Engl J Med 21 (2008) 976-983
126. Pritchard K.I., Messersmith H., Elavathil L., et al. HER2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26 (2008) 736-744
127. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplication of the HER2/neu oncogene. Science 235 (1987) 177-182
128. Wolff A.C., Hammond M.E., Schartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
129. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 353 (2005) 1673-1684
130. Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
131. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26 (2008) 1231-1238
132. Cancer International Research Group. Press Release BCIRG 006 FDA Approval (May 29, 2008). http://64.233.183.104/search?q=cache:L6vhvabBD1QJ:www.bcirg.org/NR/rdonl (accessed Aug 7, 2008).
133. Wood E.R., Truesdale A.T., McDonald O.B., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate and receptor activity in tumour cells. Cancer Res 64 (2004) 6652-6659
134. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitibine for HER2 positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
135. Nahta R., Hung M.C., and Esteva F.J. The HER2 targetting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64 (2004) 2343-2346
136. Nahta R., Yuan L.X., Zhang B., et al. Insulin-like growth factor I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65 (2005) 1118-1128
137. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006) 1500-1508
138. Pegram M., Chan D., Cichmann R.A., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor (VEGF) using trastuzumab and bevacizumab as first-line treatment of HER2 amplified breast cancer. Breast Cancer Res Treat 100 (2006) abstract 201.
139. Hortobagyii G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62 (1988) 2507-2516
140. Wolff A.C., and Davidson N.E. Primary systemic therapy in operable breast cancer. J Clin Oncol 18 (2000) 1558-1569
141. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
142. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
143. Van der Hage J.A., van de Velde C.J.H., Julien J.-P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 (2001) 4224-4237
144. Makris A., Powles T.J., Ashley S.E., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9 (1998) 1179-1184
145. Scholl S.M., Fourquet A., Asselain B., et al. Neoadjuvant vs adjuvant chemotherapy in premenopausal women with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial. Eur J Cancer 30A (1994) 645-652
146. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 (2002) 1456-1466
147. Bear H.D., Anderson S., Brown A., et al. The effect of tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
148. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significant higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomised trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005) 3676-3685
149. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24 (2006) 1037-1044
150. Gianni L., Baselga J., Eirmann W., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11 (2005) 8715-8721
151. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
152. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathological response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
153. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis. J Natl Cancer Inst 97 (2005) 188-194
154. Davidson N.E., and Morrow M. Sometimes a great notion-an assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 97 (2005) 159-161
155. Beresford M.J., Ravichandran D., and Makris A. Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev 33 (2007) 48-57
156. Eiermann W., Paepke S., Appfelastaedt J., et al. Pre-operative treatment of post-menopausal breast cancer with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 (2001) 1527-1532
157. Smith I., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of post-menopausal breast cancer with anastrozole, tamoxifen or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen or Combined with Tamoxifen (IMPACT) Multicenter Double-Blind Randomized trial. J Clin Oncol 23 (2005) 5108-5116
158. Dixon J.M., Jackson J., Renshaw L., et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86 (2003) 295-299
159. Veronesi U., Bonadonna G., Zurrida S., et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222 (1995) 612-618
160. Beresford M., Padhani A.R., Goh V., et al. Imaging breast cancer response during neoadjuvant systemic therapy. Expert Rev Anticancer Ther 5 (2005) 907-915
161. Padhani A.R., Ah-See M.-L., and Makris A. MRI in the detection and management of breast cancer. Expert Rev Anticancer Ther 5 (2005) 239-252
162. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 (2005) 2694-2702
163. Sabel M.S., Schott A.F., Kleer C.G., et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 39 (2003) 1089-1096
164. Jordan V.C. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2 (2003) 205-213
165. Jensen E.V., and Jordan V.C. The estrogen receptor: a model for molecular medicine. The Dorothy P Landon AACR Prize for Translational Research. Clin Cancer Res 9 (2003) 1980-1989
166. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
167. Cuzick J., and Baum M. Tamoxifen and contralateral breast cancer. Lancet 2 (1985) 282
168. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44 (2008) 30-38
169. Powles T.J., Hardy J.R., Ashley S.E., et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60 (1989) 126-131
170. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
171. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 (2005) 1652-1662
172. Cuzick J., Forbes J.F., Sestak I., et al. Long term results of tamoxifen prophylaxis for breast cancer-96 month follow up of the randomized IBIS-I trial. J Natl Camcer Inst 99 (2007) 272-282
173. Powles T.J., Ashley S., Tidy A., et al. Twenty-year follow up of the Royal Marsden randomized, double blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99 (2007) 283-290
174. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 (2003) 1758-1764
175. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
176. Black L.J., Jones C.D., Falcone J.F., et al. Antagonism of estrogen action with a new benzothiaphene derived antiestrogen. Life Sci 32 (1983) 1031-1036
177. Jordan V.C. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Investl 6 (1988) 589-595
178. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
179. Martino S., Cauley J.A., Barrett-Connor E., et al., for the CORE Investigators Continuing Outcomes Relevant to Evista. Breast cancer incidence in postmenopausal osteoporotic women in a randomised trial of raloxifene. J Natl Cancer Inst 96 (2004) 1751-1761
180. Vogel V.G., Costantino J.P., Wickerham D.L., et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 295 (2006) 2727-2741
181. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
182. Jordan V.C. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Rev 7 (2007) 46-53
183. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163 (2003) 96-103